Response scheme poticelli in patients with idiopathic membranous nephropathy, Barranquilla 2011-2013
Keywords:
Ponticelli scheme, idiopathic membranous nephropathyAbstract
Objective: Assess response to Ponticelli scheme in patients with idiopathic membranous nephropathy.Barranquilla 2011-2013. Materials and methods: Analytical study type clinical trial in 21 patients with idiopathic membranous nephropathy confirmed by renal biopsy who underwent treatment according Ponticelli scheme ; were performed 24h-proteinuria, creatinine, creatinine clearance and type IV blood count at the beginning , during routine follow-up, and 6 months after completion of the scheme. Results: On admission, the mean proteinuria was 7.46 ± 4.15 g/24 hr and at six months was 1.93 ± 1.55 g/24 hr; crea- tinine at baseline was 1.43 ± 0.88 mg/dl and 1.33 ± finish the scheme 0.82 mg/dl ; complete remission was achieved in 23.8 % , partial response in 66.7 % and no therapeutic response at 9.5% is present. Conclusions: The implementation of the scheme Ponticelli produced marked diminution of proteinuria, and total or partial therapeutic response in most patients, both considered good prognostic factor in nephrotic syndrome; however, due to disagreement with some studies, such as Ponticelli , and adverse effects , is necessary to continue research in this field
Downloads
References
2.Nagaku M, Stuart J, Couser W. Cellular response to injury in Membranous Nephropathy. J Am Soc Nephrol. 2005; 16: 1195-120
3.Mezzano S, Hernando L, Aljama P, Arias M, Caramelo C, Egido J. Nefropatía membranosa. Nefrología clínica.2003; 2:302-308
4.Donadio JV, Torres VE, Velosa JA, Wagoner R, Holley KE, Offord KP, et al. Idiopathic membranous nephropathy: the natural history in untreated patients. Kidney Int. 1988; 33: 708-715
5.Wehrmann M, Bohle A, Bogenschutz O, Eissele R, Freislederer A, Ohlschlegel C, et al. Long term prognosis of idiopathic membranous glomerulo- nephritis. An analysis of 334 cases with particular regard to tubulo interstitial changes. Clin Nephrol. 1989; 31: 67-76
6.Schieppati A, Moscón L, Perna A, Mecea G, Bertari T, Garattini S, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med. 1993; 329: 85-8
7.Praga M. Tratamiento de la glomerulonefritis membranosa. Rev Nefrología. 2005; 5: 467-474
8.Base de datos Nefrored. 2012.
9.Couser W. Membranous Nephropathy: A long road but well traveled J Am Soc Nephrol. 2005; 16: 1184-1187
10.Nagaku M, Stuart J, Couser W. Cellular response to injury in Membranous Nephropathy. J Am Soc Nephrol. 2005; 16: 1195-120
11.Cattran D. Management of membranous nephro- pathy: When and what for treatment. J Am Soc Nephrol 2005; 16: 1188 – 1194
12.Flores C, Ardiles A, Blackburn T, Alruiz p, Mezzano S. Anticuerpos antifosfolípidos en nefropatía membranosa idiopática. Rev Méd Chile. 2005; 133: 287-293
13.Ponticelli C, Zucchelli P, Imbasciati E, Cagnoli L, Pozzi C, Gras C, et al. Controlled trial of methylpredniso- lone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med. 1989;310:946-950
14. Debiec H, Lefeu F, Kemper MJ, Niaudet P, Deschenes G, et al. Early-childhood membranous nephropa- thy due to cationic bovine serum albumin. N Engl J Med 2011; 364:2101-2110
15. Segarra A, Praga, Ramos N. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 2009; 4: 1083-88.
16. Troyanov S, Wall CA, Miller JA, Scholey TW, Cattran DC. Idiopathic membranous nephropathy: defini- tion and relevance of a partial remission. Kidney Int 2004; 66:1199-1205.
17. Hogan S, Muller KE, Jennette JC, Falck RG. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 1995; 25: 862-75
Downloads
Published
Issue
Section
License
-
Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios<. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
-
NoComercial — No puede utilizar el material para una finalidad comercial.
-
CompartirIgual — Si remezcla, transforma o crea a partir del material, deberá difundir sus contribuciones bajo la misma licencia que el original.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
